Antidepressants Linked To Cataract Risk; Parkinson’s Drug May Cause Corneal Damage
March 28th, 2010
This month’s Ophthalmology, the journal of the American Academy of Ophthalmology, includes new studies on links between eye diseases and two widely-prescribed drugs: SSRI (selective serotonin reuptake inhibitor) antidepressants, and amantadine, a Parkinson’s disease treatment.
Seniors who take SSRI antidepressants may be more likely to develop cataracts , says the first major study to examine this […]
Smaller Babies Delivered By Depressed Mothers
March 28th, 2010
Clinical depression and anxiety during pregnancy results in smaller babies that are more likely to die in infancy, according to new research published in the open access journal BMC Public Health.
The study, which focused on women living in rural Bangladesh, provides the first finding of its kind in a non-Western population. The research indicates that […]
Wall Street Comes To Washington, And, Gasp, Health Care Consensus Ensues : Shots - Health News Blog : NPR
March 27th, 2010
Wall Street Comes To Washington, And, Gasp, Health Care Consensus Ensues
Financial and health policy analysts who gathered for the 15th annual Wall Street Comes to Washington Conference reached a surprising meeting of the minds on the new health care law.
They nearly all said it will do a good job getting people more insurance coverage, and […]
Generics As Good As Expensive New Blood Pressure Meds
March 26th, 2010
Expensive brand-name medications to lower blood pressure are no better at preventing cardiovascular disease than older, generic diuretics, according to new long-term data from a landmark study.
Paul Whelton, MB, MD, MSc, reported the results on Aug. 13 at the plenary session of the China Heart Congress and International Heart Forum in Beijing. Whelton is president […]
Cleviprex Results Reported From Study In Patients With Intracerebral Hemorrhage
March 22nd, 2010
First reported interim data from the Evaluation of patients with acute hypertension and intracerebral hemorrhage with intravenous clevidipine treatment (ACCELERATE) trial were presented today at the Neurocritical Care Society (NCS) 2009 Annual Meeting, showing that Cleviprex (clevidipine butyrate) effectively